BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap

/in , /by

Recent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]

Read more

ARPI Doublet vs Triplet Therapy in Metastatic Prostate Cancer: Real‑World Survival and the Role of PSA Nadir

/in /by

Therapy intensification in metastatic prostate cancer has expanded the repertoire of combination regimens, but it remains unclear which patients truly benefit from adding upfront docetaxel to an androgen receptor pathway inhibitor (ARPI) based doublet. A large real world cohort study using the U.S. based Patient360 Prostate dataset, which aggregates de identified electronic health records, linked […]

Read more

Emerging Real-World Evidence Suggests Differential Outcomes Between Abiraterone and Darolutamide in Hormone-Sensitive Prostate Cancer

/in /by

Agents such as abiraterone and darolutamide have demonstrated significant survival benefits in randomized clinical trials, yet direct comparative evidence between these therapies, particularly in the pre-chemotherapy setting, remains notably absent. A recent retrospective cohort analysis leveraging the TriNetX database attempts to address this gap by comparing real-world outcomes in patients treated with ADT plus either […]

Read more

CT‑Measured Muscle Quality Predicts Survival in Men with Non‑Metastatic Castration‑Resistant Prostate Cancer

/in /by

Researchers in Japan have found that muscle “quality,” not just size, is linked to how long men with non‑metastatic castration‑resistant prostate cancer (nmCRPC) live, even when they are treated with androgen receptor signaling inhibitors. The study analyzed 344 men using standard CT scans to measure muscle quantity and the amount of fat inside the muscle, […]

Read more

Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use

/in /by

A new analysis reports the development of a simple clinical score that may help physicians better identify which men are most likely to benefit from treatment with cabazitaxel after disease progression on earlier therapies. The work, based on a post-hoc analysis of the CABASTY study and validated in two major phase-3 trials, suggests that survival […]

Read more

Immune‑transcriptomic correlates of response to alpha‑ versus beta‑emitting PRRT in neuroendocrine tumors

/in , /by

Peptide receptor radionuclide therapy (PRRT) is being used more often to treat certain solid tumors, such as neuroendocrine tumors that express somatostatin receptors and some prostate cancers. One form of PRRT uses a beta‑emitting drug (177Lu‑DOTATATE), which is currently the standard treatment for many of these neuroendocrine tumors. Another, newer approach uses an alpha‑emitting drug […]

Read more

Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC

/in , /by

A large real‑world study in nonmetastatic castration‑resistant prostate cancer (nmCRPC) called DEAR‑EXT, published on Nature, has added new detail to how the three androgen receptor inhibitors (darolutamide, enzalutamide, and apalutamide) behave outside of randomized trials, using data from over 1,300 men treated in US urology practices between 2019 and 2023. The analysis builds on an […]

Read more

CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings

/in /by

Skeletal muscle index measured from regular CT scans works as a simple marker to predict outcomes and treatment response in newly diagnosed hormone-sensitive prostate cancer, based on this STAMPEDE study review. Low muscle, or sarcopenia, is common in advanced prostate cancer and gets worse with hormone therapy, but skeletal muscle index (SMI) uses psoas muscle […]

Read more

Genomic Alterations and LuPSMA Outcomes in mCRPC: A Prognostic Insight

/in /by

Genomic alterations like TP53, PTEN, and RB1 mutations are prevalent in metastatic castration-resistant prostate cancer (mCRPC), yet their impact on response to 177Lu-PSMA-617 (LuPSMA, Pluvicto) radioligand therapy remains underexplored. A recent retrospective study published in the Journal of Nuclear Medicine analyzed 72 mCRPC patients treated with at least one cycle of LuPSMA between October 2022 […]

Read more

Docetaxel Rechallenge vs Cabazitaxel in mCRPC: VA Cohort Study

/in /by

A retrospective cohort study published January 2, 2026, in JAMA Network Open compared docetaxel rechallenge to cabazitaxel in 669 patients with metastatic castration-resistant prostate cancer treated in the Veterans Affairs healthcare system from 2010 to 2023. All patients had received at least three cycles of initial docetaxel without disease progression and then one intervening systemic […]

Read more